ASCO 2015 Highlights

Genetic Abnormality Pinpointed for Intensive Therapy in Wilms Tumor

Phoebe Starr

July 2015, Vol 6, No 6 - ASCO 2015 Highlights

Chicago, IL—In children who are at risk for Wilms tumor, the presence of a rare genetic abnormality identifies children who can have a survival benefit from the augmentation or intensification of therapy. The abnormality—loss of heterozygosity (LOH) on chromosomes 1p and 16q (LOH 1p/16q)—is associated with worse prognosis in children with Wilms tumor. [ Read More ]

Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma

Wayne Kuznar

July 2015, Vol 6, No 6 - ASCO 2015 Highlights

Chicago, IL—Lenvatinib (Lenvima) added to everolimus (Afinitor) extended overall survival (OS) significantly compared with everolimus alone in patients with metastatic renal-cell carcinoma (RCC). This phase 2 study also demonstrated improved progression-free survival (PFS) with lenvatinib alone and in combination with everolimus compared with everolimus alone. [ Read More ]

Docetaxel Boosts Survival in Patients with Hormone-Naïve Metastatic Prostate Cancer

Phoebe Starr

June 2015, Vol 6, No 5 - ASCO 2015 Highlights

Chicago, IL—Adding docetaxel (Taxotere) to standard hormone therapy extends overall survival (OS) by a median of 10 months versus hormone therapy alone in men with newly diagnosed, advanced, hormone therapy–naïve prostate cancer, according to the results of the STAMPEDE trial. The survival benefits were more pronounced in metastatic disease and were less certain in nonmetastatic disease. Another finding of this analysis of STAMPEDE is that zoledronic acid (Zometa) had no benefit in this setting. [ Read More ]

Immunotherapy Makes Headwinds into Liver Cancer

Wayne Kuznar

June 2015, Vol 6, No 5 - ASCO 2015 Highlights

Chicago, IL—Immunotherapy with nivolumab (Opdivo) resulted in durable responses and promising overall survival (OS) in a dose-escalation and expansion trial of patients with advanced liver cancer. The 12-month OS rate exceeded 60% in patients in whom sorafenib (Nexavar) had failed, and responses occurred in patients with the hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, reported Anthony B. El-Khoueiry, MD, Assistant Professor of Clinical Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, at the 2015 American Society of Clinical Oncology (ASCO) meeting. [ Read More ]

Oral Nicotinamide Prevents Common Skin Cancers in High-Risk Patients

Phoebe Starr

June 2015, Vol 6, No 5 - ASCO 2015 Highlights

Chicago, IL—The prevention of common skin cancers and precancers is possible by taking an inexpensive, widely available, oral pill twice daily. The pill—the vitamin B3 supplement called nicotinamide—cut the rate of new squamous-cell and basal-cell skin cancers by 23% compared with placebo after 1 year among patients at high risk for skin cancer. Nicotinamide also reduced the risk for developing actinic keratosis, a common precancer of the skin. [ Read More ]